Legalization The CBD industry in Japan has recently garnered the attention of publicly listed companies, who have made their first investments after the country’s legalization.

AstraSana Japan Co., Ltd. has announced a strategic partnership with GSI Creos Corporation, one of Japan’s leading trading companies. This alliance will strengthen the distribution of CBD raw materials across Japan and provide customers with safe and reliable products of the highest quality.

The AstraSana Group, based in Switzerland, is committed to delivering Swiss-made, high-quality CBD raw materials to customers in Japan. With this partnership, the company aims to establish a stable supply chain and prioritize customer satisfaction.

Through this collaboration, AstraSana will leverage GSI Creos’ extensive resources and networks to provide even higher-quality services to customers. The company also plans to actively contribute to the growth and development of the CBD market through various approaches.

“At AstraSana Japan, we prioritize safety through third-party analyses and ensure the delivery of superior-quality products. Our goal is to enhance customers’ ‘Quality of Life’ (QOL) while staying at the forefront of technological innovation,” said a spokesperson for AstraSana.

The potential of CBD in the Japanese market is rapidly expanding, with global demand on the rise. As CBD is legally recognized as a safe material in Japan, this partnership will strengthen AstraSana’s supply chain and promote the availability of safe and reliable CBD products across the country.

GSI Creos Corporation is an innovative trading company with nine domestic and 24 international bases. The company operates globally in both “textiles” and “industrial products” and is committed to creating a better quality of life for the next generation through ESG management.

“We are excited to partner with AstraSana and contribute to the growth of the CBD market in Japan. Our shared commitment to quality and customer satisfaction makes this alliance a perfect fit,” said a spokesperson for GSI Creos.

The AstraSana Group, headquartered in Zurich, Switzerland, specializes in cannabinoid raw materials and medical cannabis. The company operates through affiliates in the Czech Republic, the UK, and Japan and continues to expand its global reach through collaborations with partners in Europe and South America.

For more information, please visit the AstraSana Holding AG website or contact Yves Antoniazzi at info@astrasana.com.

Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.

Leave a Reply

Your email address will not be published. Required fields are marked *